OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutical Targets in Allergic Inflammation
Lorenzo Salvati, Francesco Liotta, Francesco Annunziato, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2874-2874
Open Access | Times Cited: 11

Showing 11 citing articles:

CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease
Raquel Gómez-Bris, Ángela Saéz, Beatriz Herrero‐Fernández, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2696-2696
Open Access | Times Cited: 109

Skin, gut, and lung barrier: Physiological interface and target of intervention for preventing and treating allergic diseases
Roberto Berni Canani, Marco Caminati, Laura R. Carucci, et al.
Allergy (2024) Vol. 79, Iss. 6, pp. 1485-1500
Open Access | Times Cited: 19

T helper cell subsets: diversification of the field
Christina E. Zielinski
European Journal of Immunology (2023) Vol. 53, Iss. 12
Open Access | Times Cited: 25

Management of Atopy with Dupilumab and Omalizumab in CADINS Disease
Natalie M. Diaz-Cabrera, Bradly M. Bauman, Mildred A. Iro, et al.
Journal of Clinical Immunology (2024) Vol. 44, Iss. 2
Closed Access | Times Cited: 3

High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis
Ao Wang, Yuan Zhou, Yang Luo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9

Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status
Klaus F. Rabe, Ian Pavord, William W. Busse, et al.
Allergy (2023) Vol. 78, Iss. 8, pp. 2148-2156
Open Access | Times Cited: 5

Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives
Tong Li, Jiali Yin, Yujuan Yang, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 8, pp. 939-948
Closed Access | Times Cited: 5

A Mouse Model for Eosinophilic Esophagitis (EoE)
Anish Dsilva, Shmulik Avlas, Natalie Rhone, et al.
Current Protocols (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 1

A decade of USFDA-approved small molecules as anti-inflammatory agents: Recent trends and Commentaries on the “industrial” perspective
Vikrant Mehta, Ashish Ranjan Dwivedi, Abhilash Ludhiadch, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115942-115942
Closed Access | Times Cited: 3

Asthma and COPD: A Focus on β-Agonists – Past, Present and Future
Jillian G. Baker, Dominick Shaw
Handbook of experimental pharmacology (2023)
Closed Access | Times Cited: 1

Page 1

Scroll to top